Home

vendeur Camion lourd corde novartis zolgensma press release Volcanique Marguerite jambe

EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology

Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma

Novartis releases long-term Zolgensma data
Novartis releases long-term Zolgensma data

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube
Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients

FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian

Test Achats porte plainte contre un médicament à 2 millions d'euros
Test Achats porte plainte contre un médicament à 2 millions d'euros

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA

Novartis releases long-term data for SMA gene therapy
Novartis releases long-term data for SMA gene therapy

Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times

AMM européenne pour Scemblix® (asciminib) de Novartis
AMM européenne pour Scemblix® (asciminib) de Novartis

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest

FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association

Novartis' 'full-court press' key to ensuring rapid Zolgensma access
Novartis' 'full-court press' key to ensuring rapid Zolgensma access

Novartis to Open New Trial of Zolgensma for Older SMA Patients
Novartis to Open New Trial of Zolgensma for Older SMA Patients

Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold

Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma